Pregnancy-specific glycoproteins as potential drug targets for female lung adenocarcinoma patients
Briefings in Functional Genomics · 2025
DOI: 10.1093/bfgp/elaf004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Briefings in Functional Genomics, 2025. Verfasst von Jung Hun Oh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 321 E 61st Street, New York, NY 10065, United States. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms, Glycoproteins, Pregnancy Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Breast Cancer Research Foundation, NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Recently, the mRNA presence of pregnancy-specific glycoproteins (PSGs) in cancer biopsies has been shown to be associated with poor survival. Given the pregnancy-related function of PSGs, we hypothesized that PSGs might act in a sex-dependent behavior in cancer patients. A differential sex effect of PSG genes with respect to tumor immune landscape and cancer outcomes was investigated using statistical, bioinformatic, and machine learning analyses in The Cancer Genome Atlas (TCGA) data. The resulting findings were then validated in the Clinical Proteomic Tumor Analysis Consortium (CPTAC) data. In a pan-cancer TCGA data analysis, the strongest PSG-related sex difference for the prognostic association was found in lung adenocarcinoma (LUAD). Kaplan–Meier analysis revealed that expression of PSG genes is strongly associated with overall survival rate in the female group on the TCGA, but not in the male group. This sex-specific association was validated in an independent dataset from the CPTAC study. A combination of PSG3, PSG7, and PSG8 expression was most significantly linked to poor prognosis in females (P = 8.67E-06 in TCGA and P = .0382 in CPTAC). Pathway analysis revealed enrichment of the ‘KRAS Signaling Down’ pathway in the high-risk female group. A predictive model showed good predictive performance for the female group (validated C-index = 0.78 in CPTAC), but poor predictive performance for the male group. These findings suggest that PSGs may have a sex-specific negative impact on survival in female LUAD patients, and the mechanism may be related to KRAS signaling pathway modulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 321 E 61st Street, New York, NY 10065, United States.
- Human Oncology and Pathogenesis Program, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, United States.
- Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, United States.
- Department of Pathology, Uniformed Services University of Health Sciences, 4301 Jones Bridge Rd, Bethesda, MD 20814, United States.
ORCID-Profile: Jung Hun Oh
Förderung
- Breast Cancer Research Foundation
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Oh, J. H., Rizzuto, G., Elkin, R., Weistuch, C., Norton, L., Dveksler, G., & Deasy, J. O. (2025). Pregnancy-specific glycoproteins as potential drug targets for female lung adenocarcinoma patients. Briefings in Functional Genomics. https://doi.org/10.1093/bfgp/elaf004
Vancouver
Oh JH, Rizzuto G, Elkin R, Weistuch C, Norton L, Dveksler G, et al. Pregnancy-specific glycoproteins as potential drug targets for female lung adenocarcinoma patients. Briefings in Functional Genomics. 2025. doi:10.1093/bfgp/elaf004
BibTeX
@article{Oh2025,
author = {Oh, Jung Hun and Rizzuto, Gabrielle and Elkin, Rena and Weistuch, Corey and Norton, Larry and Dveksler, Gabriela and Deasy, Joseph O},
title = {Pregnancy-specific glycoproteins as potential drug targets for female lung adenocarcinoma patients},
journal = {Briefings in Functional Genomics},
year = {2025},
doi = {10.1093/bfgp/elaf004}
}
EUVIMED